PharmaTher inks exclusive North America deal for CraftMake 3D printing platform
PharmaTher has announced an exclusive distribution agreement for Craft Health’s CraftMake pharmaceutical 3D printing platform in North America. The deal covers printers, software, printable formulations, consumables, and services, and targets a wide range of customers from pharmacies to hospitals and government bodies.
What changed and what this means
The company says PharmaTher becomes the sole distributor in North America for Craft Health’s CraftMake system, including the CraftControl software, CraftBlends formulations, consumables, and related services. This expands PharmaTher’s role beyond distribution to potential involvement in 503A/503B compounding, telehealth partnerships, and CDMO or white-label services. The arrangement is described as exclusive, meaning Craft Health would not appoint another North American distributor for the same products and services.
Key facts to understand
- CraftMake platform includes hardware (3D printers), software (CraftControl), printable drug formulations (CraftBlends), and support services.
- Exclusive North American distributor: PharmaTher handles the U.S. and Canadian markets across multiple customer segments.
- Target audiences include compounding pharmacies (both 503A and 503B), telehealth and digital health firms, CDMOs, hospitals, universities, research and government bodies, and biotech/pharma companies.
- Potential locations and scale: PharmaTher estimates more than 10,000 potential placement sites in North America.
Who is affected
Directly affected are North American buyers of CraftMake products via PharmaTher, including compounding pharmacies, hospitals, academic and government institutions, and companies in biotech and digital health. Indirectly, patients and consumers could be impacted if 3D-printed pharmaceutical products or related services expand in availability or change how certain treatments are prepared or delivered.
Practical next steps for readers
- If you or your organization uses or plans to use 3D-printed pharmaceuticals, contact PharmaTher or your current supplier to confirm how the exclusive arrangement affects sourcing, pricing, and support.
- Ask about regulatory compliance, especially for 503A/503B compounding and any FDA-related requirements for 3D-printed drug products.
- Review timelines for rollout in your region and what training or software updates may be necessary to access CraftMake tools.
- Monitor announcements from PharmaTher and Craft Health for updates on site deployment, safety testing, and performance standards.
Limits and questions to consider
Specific regulatory standards, quality control, and patient safety obligations will depend on how the CraftMake system is used in different settings. The article underlying the deal does not provide details on regulatory submissions, oversight, or prosecution in various jurisdictions. Readers should seek official statements from PharmaTher and Craft Health for precise conditions of exclusivity, service levels, warranty terms, and any regional limitations.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- investingnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.